Sanofi SA (SASY.BE)

SASY.BE on Berlin Stock Exchange

75.66EUR
11 Jul 2014
Price Change (% chg)

€-0.75 (-0.98%)
Prev Close
€76.41
Open
€75.66
Day's High
€75.66
Day's Low
€75.66
Volume
--
Avg. Vol
8,349
52-wk High
€80.48
52-wk Low
€69.80

SASY.BE

Chart for SASY.BE

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.55
Market Cap (Mil.): €100,123.00
Shares Outstanding (Mil.): 1,322.62
Dividend: 2.80
Yield (%): 3.70

Financials

  SASY.BE Industry Sector
P/E (TTM): 26.74 35.49 35.83
EPS (TTM): 2.83 -- --
ROI: -- 19.02 18.29
ROE: -- 19.80 19.18
Search Stocks

Sanofi dengue vaccine promising but questions remain

PARIS - The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease. | Video

11:28am EDT

RPT-Sanofi dengue vaccine promising but questions remain

(Repeats with no change to text to reach more subscribers)

3:55am EDT

Sanofi dengue vaccine promising but questions remain

PARIS - The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease.

10 Jul 2014

Sanofi dengue vaccine promising but questions remain

* Currently no vaccine for expanding mosquito-borne disease

10 Jul 2014

Regeneron drug tames eczema in study

PARIS/NEW YORK - An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema that is poorly controlled by standard drugs, the companies said on Wednesday.

09 Jul 2014

Sanofi-Regeneron drug tames eczema in study

PARIS/NEW YORK, July 9 - An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema that is poorly controlled by standard drugs, the companies said on Wednesday.

09 Jul 2014

Sanofi sues Eli Lilly over insulin rival to Lantus

- Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices used to deliver it.

08 Jul 2014

Sanofi sues Eli Lilly over insulin rival to Lantus

July 8 - Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices used to deliver it.

08 Jul 2014

European shares retreat after weak German data

LONDON, July 7 - European stock markets retreated on Monday after weak German economic data took the wind out of a rally that had pushed a leading regional index back towards 6-1/2 year highs.

07 Jul 2014

European shares retreat after weak German data

* FTSEurofirst 300 down 0.6 pct, still near 6-1/2 year high

07 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks